Navigation Links
Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
Date:5/7/2009

MACCLESFIELD, England, May 7 /PRNewswire-FirstCall/ -- Cyprotex today (7th May 2009) launches Cloe(R) Gateway, a new secure web portal for access to drug discovery services. The initial offering via Cloe(R) Gateway is a new enhanced version of our proprietary predictive software, Cloe(R) PK, which predicts whole body pharmacokinetics from simple in vitro ADME and physicochemical properties.

Commenting on the launch, Dr Anthony D. Baxter, Cyprotex's Chief Executive Officer, said:

"I am delighted to announce the launch of our new and novel web portal Cloe(R) Gateway and its first product, an improved version of Cloe(R) PK. Cloe(R) PK, as a server based product, has been used by many of our customers for prediction of pharmacokinetic properties from early ADME data and found it to be very useful in decision making for candidate selection. Cyprotex have invested considerable time and effort improving the Cloe(R) PK model and we are proud to launch version 2.1 as an online service available via Cloe(R) Gateway. This will enable many more of our customers to utilise this excellent product on a simple pay-per-use model. The cost effectiveness of this approach will allow access of such predictive technologies to new audiences of scientists such as bench medicinal chemists. This approach to selling software solutions is new to the ADME / pharmacokinetic world and we anticipate it will grow to replace competitor products still being sold on the outdated server / license model.

The pharmaceutical industry has amassed a huge quantity of ADME data over the past few years and the availability of an online version of Cloe(R) PK though Cloe(R) Gateway will enable those companies to realise tremendous real added value from that data in the form of pharmacokinetic performance characteristics to enable faster, cheaper and better designed drugs to be developed.

I look forward to announcing further new products to be sold through Cloe(R) Gateway such as a human intestinal absorption model and a product to enable customers to access our largest selling product Cloe(R) Screen in the near future."

    For further information:
    Cyprotex PLC
    Helen Gill PhD, Product Development Manager
    Tel: +44(0)1625-505-100
    h.gill@cyprotex.com
   http://www.cyprotex.com


'/>"/>
SOURCE Cyprotex Discovery Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
2. Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
3. Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tephas Proprietary Biomaterial
4. Elsevier Launches Ten New eBook Specialty Collections on MD Consult
5. Histogen Aesthetics Launches ReGenica Rejuvenation System
6. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
7. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
8. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
9. Cell Biosciences Launches Next-Generation Protein Characterization System
10. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):